RPS6KA2

Across TCGA pan-cancer cohorts, RPS6KA2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPS6KA2 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RPS6KA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS6KA2 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

ESCA, PRAD, and LUSC are the cancer types where RPS6KA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.095	0.681	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	All	1.000	0.371	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPS6KA2–ESCA (OS)

Open the ESCA breakdown →